Vivo Bio Tech Ltd (VIVOBIOT) — shareholding pattern, promoter holding, financials and share price
About Vivo Bio Tech Ltd (VIVOBIOT)
Vivo Bio Tech Ltd operates in the Biotechnology industry, within the Healthcare sector. It trades on the NSE as VIVOBIOT and on the BSE under scrip code 511509. Its ISIN is INE380K01017.
Incorporated in 1987, Vivo Bio Tech Ltd is engaged in service of CRO offering Drug Development & Discovery Services to Pharmaceutical & Biotech Companies [1]
Vivo Bio Tech Limited is a full-service Contract Research Organization (CRO) providing drug development and discovery services globally. It specializes in preclinical testing, offering both in-vitro and in-vivo studies.
The company has established itself as India's largest breeder and distributor of rodent models, providing SPF lab animals for preclinical studies.
Listed peers in Biotechnology: Vasundhara Rasayans Ltd, Biofil Chemicals & Pharmaceuticals Ltd, Bacil Pharma Ltd, Kabra Drugs Ltd, Vivimed Labs Ltd, Shelter Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹23.51 a share on 10 Jul 2026, Vivo Bio Tech Ltd (VIVOBIOT) was valued at a price-to-book of 0.57x on a book value of ₹41.25 per share. Solomo computes return on equity of -1.83% and return on capital employed of 6.64% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 0.57x
- EPS (TTM)
- ₹-0.77
- Book value / share
- ₹41.25
- ROE
- -1.83%
- ROCE
- 6.64%
- ROA
- -0.95%
- Debt / equity
- 0.72x
- Dividend yield
- 0%
- EBITDA margin
- 39.92%
- 52-week range
- ₹20.35 – ₹43.35
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vivo Bio Tech Ltd (VIVOBIOT) reported revenue of ₹53.33 crore, net profit of ₹-1.71 crore and earnings per share of ₹-0.77. That compares with revenue of ₹46.67 crore and net profit of ₹7.28 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2026, revenue was ₹14.28 crore and net profit ₹0.19 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 51.39 | 52.23 | 45.45 | 46.67 | 53.33 |
| Net profit (₹ cr) | 2.2 | 2.65 | 2.53 | 7.28 | -1.71 |
| EPS (₹) | 1.54 | 1.78 | 1.7 | 4.24 | -0.77 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.60% | -3.35% | -3.16% | 2.68% |
| Profit growth | 26.54% | 11.24% | 50.90% | 187.75% |
| Stock price CAGR | -5% | -23% | -4% | -36% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.62% of Vivo Bio Tech Ltd (VIVOBIOT) (down 4.81 pp QoQ). Market capitalisation was ₹52 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2002.
Largest disclosed public shareholders in Jun 2026: ANTIQUE INFOTECH PRIVATE LIMITED 11.71%, DWIGHT TECHNOLOGIES PRIVATE LIMITED 8.44%, ELITE CLASS ASSET HOLDINGS LTD 5.86%, MORE AGRISUPPLIES AND SERVICES PRIVATE LIMITED 3.57%, EVERY WEAR IMPORT AND EXPORT PRIVATE LIMITED 1.61%, MALLEMKONDA REALITIES PRIVATE LIMITED 1.58%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.62% | - | - | - | 69.38% |
| Mar 2026 | 35.43% | - | - | - | 64.57% |
| Dec 2025 | 35.16% | - | - | - | 64.84% |
| Sep 2025 | 35.16% | - | - | - | 64.84% |
| Jun 2025 | 39.06% | - | - | - | 60.94% |
| Mar 2025 | 40.85% | - | - | - | 59.15% |
| Dec 2024 | 38.88% | - | - | - | 61.12% |
| Sep 2024 | 42.08% | - | - | - | 57.92% |